Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NUjR[GduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\jW2lvOi53IN88US=> MYixMVQh\A>? MlSzSG1UVw>? NUPQXGRb\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NIi2T5IzPTR7MEO4Ny=>
H1703 NWq5Ull6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXpNk42KM7:TR?= M4rOTVEuPCCm M{PhfWROW09? NXewOmNm\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? Mn;XNlU1QTB|OEO=
HUVECs NYq5UZR3S3m2b4TvfIlkcXS7IFHzd4F6 NUHZZ45nOTByIH7N NEHmT2EzPCCq NEOwZVlifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MUmyOVQ2ODF6Nh?=
APRE-19 NGnQV|dCeG:ydH;zbZMhSXO|YYm= MX[1JO69VQ>? MXKyOEBp NF\Ue5hi[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= NVy3S4xKOjV|Mkm2NVc>
MDA-MB-231 MUHBdI9xfG:|aYOgRZN{[Xl? NEHpfZIyyqEQvF5CpC=> MmLIOFghcA>? NGrI[FhFVVOR MVfk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= M17tfVI2OzByOUOy
MCF7 MXTGeY5kfGmxbjDBd5NigQ>? Mn\2NVAxKG6P NU\kdJR5OjRiaB?= M17rVYVtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 NYrnO2tOOjVzN{K1OVc>
HT-29  MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DtOVEvPcLiwsXN NFj6NGM6PiCq Ml;U[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= M1;GcFI2ODF{MUKz
MO59K  Mk\XR5l1d3SxeHnjbZR6KEG|c3H5 M3\UXFXDqM7:TR?= NVz1WFc3PyCm M3q4WmROW09? M1G5b4VvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M{fFVVI1QTV|NU[x
MO59J MXjDfZRwfG:6aXPpeJkhSXO|YYm= NGf4XnQ2yqEQvF2= NGLtV|A4KGR? MoT5SG1UVw>? M3TscoVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MUSyOFk2OzV4MR?=
MO59K  NWXDTItySXCxcITvd4l{KEG|c3H5 MX2xNEDPxE1? M3[yc|I1KGh? M1zNZWROW09? M373XYlv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NX\zVotZOjR7NUO1OlE>
MO59J NWnWO5p1SXCxcITvd4l{KEG|c3H5 NIPsOVcyOCEQvF2= MWOyOEBp NEDvbWRFVVOR M3niUolv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? MXWyOFk2OzV4MR?=
HepG2 M{S1RmZ2dmO2aX;uJGF{e2G7 MUSxNFAhdk1? M1P1NFAvPSCq M3zNT2ROW09? M{HaVYJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MmDXNlQ5PjN|NUC=
A549  NUnWbllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3jN{DDvU4EoB?= NEDhO28zKGh? MVrzeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v Mny5NlQ5PDd6NkO=
A549  NWXKOXlCTnWwY4Tpc44hSXO|YYm= MnnxNVDDqM7:bdMg MVSxOkBp M{Lxd2ROW09? Mlr5cY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu NFXUXFYzPDhyMkGxNS=>
SK-N-LO NH:ySmpHfW6ldHnvckBCe3OjeR?= NV74WWoyOTByIH7N NXjjb3p4OC53IHi= NEf3NY5l\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? NHPtVHYzPDZ3NE[wOi=>
HL-60 Ml;3SpVv[3Srb36gRZN{[Xl? MXiwMlHDqM7:TR?= MmD3O|IhcA>? NVTiR3lr[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v MoDJNlQ3ODd{N{O=
HepG2  NFPpXIZHfW6ldHnvckBCe3OjeR?= M4DpTFIxOCCwTR?= M2fUbFAvPSCq MY\heJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v Mn36NlQ2OzVzOUK=
H520 MWHGeY5kfGmxbjDBd5NigQ>? NWfoPZdTOTEEoN88US=> NEPud3AyKGh? NVTsV25nTE2VTx?= MWDk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NX7We|dUOjR2NEe5N|U>
H1975 NWLLXYwzTnWwY4Tpc44hSXO|YYm= MUexNOKh|ryP NY\EWZBrOSCq NXPJNXVjTE2VTx?= MnjF[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NWDET|V{OjR2NEe5N|U>
MG-63 NGjrepZCeG:ydH;zbZMhSXO|YYm= NWnxfGYyOTBiwsXN Mlz6NVIhcA>? NIruWHpmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? M1H1e|I1OzV6M{Cx
5637 M2D6TGFxd3C2b4Ppd{BCe3OjeR?= MXexNOKh|ryP M4Dm[|QxKG2rbh?= NUiyWlFSemW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw M3vuV|I1OzN|OE[4
HEK-293 NEG0e2lHfW6ldHnvckBCe3OjeR?= MXOxOVBvVQ>? NEHGZYIyPiCq NF\ISYxFVVOR NXe3R5BJ\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= M3PBRVI1OzJ2M{[2
SW480  MmjqSpVv[3Srb36gRZN{[Xl? MnvlNVUxdk1? MW[yNEBp MkPXSG1UVw>? MVvy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw NVP6S|NIOjR|MkSzOlY>
HepG2 NWnjR4hKTnWwY4Tpc44hSXO|YYm= NV35XVZyOTByIH7N MnHENlQhcA>? NIHOfJVifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= Mme2NlQzQTd3MUC=
HCT 116  MVnGeY5kfGmxbjDBd5NigQ>? Ml\3NVAxKG6P MXmyOEBp M{HJNoF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz NGPjSZMzPDJ7N{WxNC=>
BEL/FU NWW2bW96TnWwY4Tpc44hSXO|YYm= MofGNUBuVQ>? NXHLVm92OjRiaB?= MVPk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> MXmyOFI{OjB7OR?=
Huh7  MWTGeY5kfGmxbjDBd5NigQ>? NFzjeI4{yqEQvF2= NEm0RoYyKGh? NVPCZ3VCemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? NXzPTGw{OjRzOESxPVY>
A-375 MnrGRZBweHSxc3nzJGF{e2G7 MlP4OE85KM7:TR?= MV2yOEBp M3zBe4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= M{nXN|I1OTF|MUez
A-375-TS  M2XQZmFxd3C2b4Ppd{BCe3OjeR?= M4\aOFQwQCEQvF2= NGHrNJQzPCCq MmLk[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NYrRU4lEOjRzMUOxO|M>
Mel-HO NVfUfmRQSXCxcITvd4l{KEG|c3H5 MXG0M|gh|ryP MoD6NlQhcA>? NWPLbWxz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MVSyOFEyOzF5Mx?=
Mel-HO-TS NYnXUYlOSXCxcITvd4l{KEG|c3H5 MU[0M|gh|ryP NHrLSmQzPCCq NVj0NY5Z\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NGLPOpozPDFzM{G3Ny=>
MeWo NYi4SnBkSXCxcITvd4l{KEG|c3H5 NWjp[IoyPC96IN88US=> NXKy[VRmOjRiaB?= NILFOHlmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MV2yOFEyOzF5Mx?=
Mel-2a NHWxVVJCeG:ydH;zbZMhSXO|YYm= MWW0M|gh|ryP NYHaUVB2OjRiaB?= M2jjfIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MnvwNlQyOTNzN{O=
MDA-MB-231 M{\YWWZ2dmO2aX;uJGF{e2G7 MlfHNQKBmzRyMDDuUS=> NGjOUmM1KGh? NV;wZnZFe3WycILld5NmeyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXLvN5I6OjJ7ME[yOVk>
MDA-MB-231 M3jrdmZ2dmO2aX;uJGF{e2G7 NVnGSG05PDByIH7N NFrJU|g1KGh? M4G1T4Rm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIDLVY8zOjlyNkK1PS=>
Jurkat MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMlI2NTFwMkWg{txO NX:5c3BSOjRxNEigbC=> MlL2SG1UVw>? NInWRnpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MX6xPVc2PzF6NR?=
Namalwa NFjJT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliyNE4zPS1zLkK1JO69VQ>? NEe0dIMzPC92ODDo NEfKS|ZFVVOR MYPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NUPv[YszOTl5NUexPFU>
Jurkat MoHTRZBweHSxc3nzJGF{e2G7 NXzY[ZhzOC5{NT2xMlI2KM7:TR?= MkDKNlQwPDhiaB?= MlvQSG1UVw>? NYTkXGJocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MnrDNVk4PTdzOEW=
Namalwa MUfBdI9xfG:|aYOgRZN{[Xl? M37EWFAvOjVvMT6yOUDPxE1? Mn;CNlQwPDhiaB?= M4PXSGROW09? MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NGi2c3QyQTd3N{G4OS=>
K562 M2T2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnzZm0zPCCq NGT0enVKSzVyPUK1xtExNjF2IH7N NXfSRmNuOTl4NkKzOlE>
SW1990 NEfxUmRHfW6ldHnvckBCe3OjeR?= M2jK[lAvODFvMTFOwG0> M4e1OVEhcA>? Mn\2bY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M4ToVlE6PDZ7MEKw
RT112  M3jsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnYb|VROTEEoN88US=> NF\3TIUzPCCq M3[4eWROW09? MkWx[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> NUnibo9EOTh5OEe4N|I>
MHG-U1 M1HVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGXFExyqEQvF2= MnX6NlQhcA>? M3LhTmROW09? NIjoZW9l\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? Mn;qNVg4QDd6M{K=
SMMC-7721 Mlj3RZBweHSxc3nzJGF{e2G7 MV2yNFDDqG6P NHnLSJIzPCCq Mk\FbY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? NGTablQyPzV3N{G5NS=>
SMMC-7721 M2jPXWZ2dmO2aX;uJGF{e2G7 NWLJUWh2OjBywrDuUS=> MYGyOEBp NETZR|V2eC2{ZXf1cIF1\XNizsKxMFRIXDFiZYjwdoV{e2mxbh?= M4XENlE4PTV5MUmx
HeLa M{nRNmZ2dmO2aX;uJGF{e2G7 MmPKNVAxyqCwTdMg MXOxJIg> MoTTZYx1\XK|IITo[UBud3KyaH;sc4d6KG:oIITo[UB1emGwc3\ldpJqdiC{ZXP5Z4xqdmdiY3;tdIFzfG2nboS= MX6xOlg6ODlzNR?=
MRC5VI MYLGeY5kfGmxbjDBd5NigQ>? NXK2Xmc{OTJwNTDtUS=> MVWwMlUhcA>? NYexXVhJTE2VTx?= MYXhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NGfD[lMyPjJ{N{O5OC=>
AT5BIVA MVTGeY5kfGmxbjDBd5NigQ>? M1nOXFEzNjVibV2= M{i2Z|AvPSCq MW\EUXNQ NEPlXo5i[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MU[xOlIzPzN7NB?=
M059J MU\GeY5kfGmxbjDBd5NigQ>? NHHSTHoyOi53IH3N MYewMlUhcA>? MWLEUXNQ MnPjZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MoKwNVYzOjd|OUS=
HeLa NIXlSVZHfW6ldHnvckBCe3OjeR?= NXnuN2RxOTJwNTDtUS=> NH;n[GkxNjViaB?= NIHLdIJFVVOR MUDhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MX:xOlIzPzN7NB?=
N2a MoPzRZBweHSxc3nzJGF{e2G7 NXfab3loOC5zLUGwJO69VQ>? NI\NXIMzKGh? NImzO2lqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MYmxOVg1Ojd4Nx?=
Jurkat  NUjDPIt1U2mwYYPlJGF{e2G7 M1\DcWlEPTBib3[gNlQhdk1? NEXXWmsyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5%DMSO+corn oil
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID